Navigation Links
Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes
Date:11/19/2009

Study Demonstrates Improvement of Accuracy with New Biosensor

FRANKLIN, Mass., Nov. 19 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced positive results of a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 Diabetes. Echo's non-invasive Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and its Prelude SkinPrep System, which incorporates leading-edge, needle-free, controlled skin ablation. Echo's Symphony tCGM System is designed to provide patients with diabetes and critical care patients with a reliable, affordable, and easy-to-use, needle-free continuous glucose monitoring device. The purpose of the study was to test the performance of its new, improved one-piece, cost-effective and easy-to-use biosensor.

"This study represents another major step forward in our Symphony development program," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We believe that we have successfully developed a new cost-effective, one-piece biosensor and, with this study, we have demonstrated improvement in the accuracy of our Symphony system glucose readings. Data from this study demonstrates that Symphony, using the new, improved, cost-effective biosensor, is safe, accurate and reliable at monitoring glucose levels. We look forward to continued progress with our Symphony development program throughout this year and next as we move toward our goal of making Symphony available to patients."

Study Design

After Prelude skin ablation, ten (10) Symphony tCGM biosensors were applied to subjects with Type 1 or Type 2 Diabetes. Venous reference blood samples were taken from
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
2. Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
3. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
4. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
5. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
6. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
7. Reportlinker Adds Pain Therapeutics 2005: Market Dynamics and Outlook
8. Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
9. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
10. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
11. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... WASHINGTON , April 16, 2015 A drug ... the eyesight of people with multiple sclerosis (MS), according to ... American Academy of Neurology,s 67th Annual Meeting in ... "About half of people with MS experience at ... neuritis, in which the nerve carrying vision from the eye ...
(Date:4/16/2015)... 16, 2015  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... 2015 on Wednesday, May 6, 2015, following the close of ... investor conference call and live webcast on the same day ... and discuss the financial results.  To access ... under the "Investors" link.  Please log onto the webcast prior ...
(Date:4/16/2015)... Mallinckrodt plc (NYSE: MNK ), ... it has completed its acquisition of Ikaria, Inc. ... The Ikaria acquisition extends Mallinckrodt,s footprint in the ... critical care with INOMAX ® (inhaled nitric ... vulnerable patient population. It also accelerates Mallinckrodt,s rapid ...
Breaking Medicine Technology:Epilepsy Drug May Preserve Eyesight for People with MS 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5
... Technologies, Inc. (NYSE Amex: PTN ) today announced ... Palatin,s request to begin a Phase 2A proof-of-concept human trial ... administered formulation of PL-3994, an NPR-A agonist compound, in development ... "We are excited about the prospect of advancing PL-3994 into ...
... 3, 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... preventive vaccines against cancers and infectious diseases, announced today that ... company overview at the ROTH 23rd Annual Growth Stock Conference ... A live and archived webcast will be accessible ...
Cached Medicine Technology:FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference 2Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference 3
(Date:4/18/2015)... Patients who undergo radiation for a hematologic cancer ... but the disease is likely to differ in some ... Surviving Mesothelioma has just posted the details of this ... read it now. , Scientists from China, the ... who had both a hematologic cancer (like lymphoma or ...
(Date:4/18/2015)... More than 2000 styles of newly designed prom dresses ... store carrying celebrity inspired special occasion dresses. With the ... dresses for their prom. For those who are still ... would be an ideal choice. , "We have ... by the most loved styles seen at this years ...
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch ... at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... , In a turbulent world, people may find themselves ... always be their first move, but some situations can be ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable assisted ... on April 20 with a day full of activities ... soul. , The community, which is located at 605 ... all incomes, including those on Medicaid, who need some ... is observed every April and highlights the communities within ...
(Date:4/17/2015)... ERGO-Pedic Products, LLC, which produces therapeutic memory foam ... help a broader range of people plagued by pain. ... most common visitors to doctors. , “The ERGO-Pedic Comfort ... relieve sitting pain. Then, only a couple months after ... later, we began getting questions from those customers, asking ...
Breaking Medicine News(10 mins):Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2
... MONDAY, Feb. 20 (HealthDay News) -- Alcohol use disorders are ... reveals. The online, anonymous poll indicated that 15 percent ... nearly 14 percent of male surgeons and 26 percent of ... 12 percent figure typically cited for alcohol abuse rates among ...
... Feb. 19 (HealthDay News) -- Even though a colonoscopy is ... many people have unfounded worries about the test and avoid ... tool that allows us to see how healthy our insides ... and a gastroenterologist at Saint Louis University, said in a ...
... Substituting smokeless tobacco products can save smokers, lives, ... That is the message Brad Rodu, D.D.S., professor ... of Medicine and the Endowed Chair in Tobacco Harm ... at the Annual Meeting of the American Association for ...
... --- Alzheimer,s disease drugs now being tested in clinical ... new Northwestern Medicine research. A study with mice suggests ... neurons to be miswired and interfering with their ability ... from the scientist whose original research led to the ...
... SATURDAY, Feb. 18 (HealthDay News) -- Two factors -- a ... critical to quality of life for disabled elderly people, according ... seniors rate their quality of life as "fair to very ... seniors (white, black, Hispanic, and Chinese American) who were interviewed ...
... 17 (HealthDay News) -- Decades-old assumptions about the odds of reaching very ... for many seniors, a new study finds. At issue is how ... A team of researchers now believe that death rates continue to rise ... bit. The findings could lead to new estimates of life span, ...
Cached Medicine News:Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 3Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 4Health News:Worries About Colonoscopy Unfounded: Study 2Health News:UofL research shows substituting with smokeless tobacco saves lives 2Health News:Alzheimer's drugs may have adverse side effects 2Health News: Disabled Elderly Say They Want Dignity, Control 2Health News:Living to 100 May Be Tougher Than You Think 2
... is an endoscopic urethral implant for ... Upon implantation, the Tegress™ Implant solution ... in a Dimethyl Sulfoxide (DMSO) carrier ... reinforces the integrity of the urethras ...
... (VZ) test system is intended ... detection of VZ IgG antibody ... indirect fluorescent antibody (IFA) technique. ... confirm a recent infection or ...
... Captia™ Varicella-Zoster Virus (VZV) IgM ... intended for the detection of ... in human serum as an ... primary infection or reactivation. For ...
... Biotech Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked ... detection and quantitative determination of IgG antibody ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
Medicine Products: